Use of multidrug-resistance gene (MDR1) expression levels to predict outcome to adjuvant cisplatin/gemcitabine based chemotherapy in patients with with locally advanced urothelial cancer

MLA

Kathleen D. Danenberg, et al. “Use of Multidrug-Resistance Gene (MDR1) Expression Levels to Predict Outcome to Adjuvant Cisplatin/Gemcitabine Based Chemotherapy in Patients with with Locally Advanced Urothelial Cancer.” Journal of Clinical Oncology, vol. 27, May 2009, p. e22081. EBSCOhost, https://doi.org/10.1200/jco.2009.27.15_suppl.e22081.

APA

Kathleen D. Danenberg, Wilfried Eberhardt, Simone Bertz, Thomas Gauler, Peter J. Wild, R. Stöhr, C. Leicht, Arndt Hartmann, Michael Stöckle, A. C. Hoffman, & Jan Lehmann. (2009). Use of multidrug-resistance gene (MDR1) expression levels to predict outcome to adjuvant cisplatin/gemcitabine based chemotherapy in patients with with locally advanced urothelial cancer. Journal of Clinical Oncology, 27, e22081. https://doi.org/10.1200/jco.2009.27.15_suppl.e22081

Chicago

Kathleen D. Danenberg, Wilfried Eberhardt, Simone Bertz, Thomas Gauler, Peter J. Wild, R. Stöhr, C. Leicht, et al. 2009. “Use of Multidrug-Resistance Gene (MDR1) Expression Levels to Predict Outcome to Adjuvant Cisplatin/Gemcitabine Based Chemotherapy in Patients with with Locally Advanced Urothelial Cancer.” Journal of Clinical Oncology 27 (May): e22081. doi:10.1200/jco.2009.27.15_suppl.e22081.